New Investor as of July 2013, but small biotech Investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.courtlistener.com/docket/18426121/alpha-venture-capital-partners-lp-v-pourhassan/?order_by=desc
Lol!
Nader Pourhassan, CEO of Cytodyn $CYDY, wins dismissal with prejudice of lawsuit by Alpha Venture Capital Partners LP in Western District of Washington Federal Court.
You do realize the company has to actually file for an EUA. If the company filed and THEN is refused an EUA, I would be more inclined to agree with your comment on the fda.
Absolutely. The claims of Leronlimab as a failure are way unsubstantiated considering everything we know up to this point collectively. Great posts, CTMedic.
A lot of buyers have already loaded up by this time. The clock is ticking on results!
“As an MD...” Who doesn’t post under a verifiable, non-anonymous twitter handle like most doctors commenting on things such as cancer or covid... No.. this one remains anonymous, without any verifiable claim as an MD.
That’s where I stop. Anonymous twitter handles have zero credibility. Why? You can’t verify their credibility!
Additionally, what’s a “Midwestern HEDGIE”? A MD? “Hedgie’” tells me more than his claim to be a MD!
Believe it or not, most of my patients are still able to talk in the hospital. So...
Or how certain individuals used despicable and self-serving methods to contact an end of life patient solely to discredit Cytodyn and potentially interfere in a clinical trial? Yeah. Let’s talk about some real ethics. Forget ‘misinformation’. That kind of action is a depth of inhumanity one should never be proud of, or pass on to your kids.
Is the company you’re referring to manufacturing a drug or therapeutic to fight against covid? I highly doubt any country would delay revenue on such a necessary and desperately sought after item right now.
The only thing is that the clinical trials website shows it is not yet recruiting.
https://www.clinicaltrials.gov/ct2/show/NCT04678830?term=leronlimab&draw=2&rank=7
However, it is also well known that the clinical trials website tends to not be updated by the required entities is a notorious happening. This is not a Cytodyn exclusive thing.
More on that aspect here:
https://www.bmj.com/content/361/bmj.k1452
Instead of speculating, why not just wait for the call? To coin a phrase, it is what it is.
Peace.
Don’t be fooled by ‘journal criticism’. We all know what really matters at the end of the day is the FDA’s acceptance of the open label protocol for Cytodyn’s phase 3 trial.
LAUGHING!
Lol. And how long have these ‘investigations’ been going? And where have they gone? That’s right! Nowhere. Solely on the emotional tantrums of investors who didn’t have the understanding or patience of a pre-revenue biotech. I’m in at 0.48c. You wanna talk loss? Talk to me when the sp dips below that. Otherwise, the science is leading this company forward.
Jump on the train or get left behind! All in my opinion of course.
LAUGHING!
Accumulating on the dips. The difference between investing versus trading in my opinion. That’s where I’m at.
That’s right, Misiu. And ‘proof’ is never enough for a constant cynic. Why waste the time?
LAUGHING!
Most longs are in at 0.48c, like myself. Fanfare not needed when the MOA and progress is going exactly as it should. LAUGHING!
Again, prayers your way Marksch1! Hopefully this will be a life saver for her! After working a Covid floor for a few months, you definitely see some pretty unusual things with Covid. Stay strong buddy!
Awesome. Got a a guy at my church who is getting compassionate use for his cancer. Three main tumors. Was told it was theoretically possible to remove one tumor, but that would cause the other two to grow faster since the three ‘compete’ for nutrition.
He had the receptor occupancy test. Only needed 10% to qualify. He’s measured at 70%. Boom! Should be hearing any moment from fda.
So happy for you and your wife Marksch1. As a nurse who works with cancer patients at times, this drug hopefully will be a huge blessing if approved.
That’s my take. Data by mid Jan. It’s possible they could even have deals solidified by end of January.
I heard that too. Would be nice. But considering the trial has not been stopped by the dsmc, it WILL complete enrollment. Data to follow.
Don’t be misled... CD-12 enrollment complete. News to come by mid-Jan/early Feb if deals aren’t in place by then too! Happy December!
The problem is that you really can’t assume everyone has it. Additionally, it’s more than just a respiratory/aerosol virus. People wearing masks for days on end, hanging them from their rear view mirror like air fresheners, not washing them, and touching them all the time. Cross contamination is a factor too. Close contact without a mask, and poor hygiene is likely going to be your biggest risk factors. Wear a mask and use good hygiene. Look at the hair salon study where both workers wore masks, and none of their clientele caught Covid from their salon.
The problem is that even with 70% vaccination rate, you still have to deal with 70% - 95% efficacy, with the assumption that you have a large group that will NOT vaccinate, and for good reason. Never buy the first model car. If the death rate with Covid was hypothetically 12% across the board, it would be different. The public is ignorant of the difference between a vaccine to prevent infection and one that is basically like tamiflu. These “vaccines” do not demonstrate ANY ability to prevent infection. Hypothetically, you could even have someone who gets the vaccine, gets infected, has little to no symptoms, and may not realize they are an asymptomatic carrier! How’s that for preventing Covid spread? And then there’s the amount of vaccines available, the ability for people to actually go in and get the infusion if that’s the one they choose, making it in for their second shot with the other....
Covid ain’t going away any time soon. Next summer at the earliest in my opinion.
“Data is a fail”.
What proof is there of that? None. Because the trial isn’t finished and the data hasn’t been compiled and released. But nice try. Revisit when full data is actually available.
No. There is no evidence that fewer people will get Covid. Additionally, the CMO of Moderna clearly stated that was not a reasonable assumption.
https://www.businessinsider.com/moderna-chief-medical-officer-vaccines-interview-2020-11
“Moderna's chief medical officer says that vaccine trial results only show that they prevent people from getting sick — not necessarily that recipients won't still be able to transmit the virus”
Another item to note is that Cytodyn is first in line for severe/critical data for mortality. AND if Leronlimab’s data shows a statistically significant cut in mortality, it will prove Leronlimab’s use in immune modulating and inflammatory conditions (I’m sure someone else can help name the numerous indications that involves).
One of the first vaccines in the race is an IV infusion. Good luck with that. The second has people demonstrating horrible side effects after the second shot, so it would be understood why some would rather risk getting Covid, getting natural immunity with it, and NOT injecting unknown substances in their bodies.
Vaccine? If it prevented transmission, maybe. But the current vaccines are just another flu shot in terms of MOA. And many people I speak to don’t realize it doesn’t prevent infectiousness.
Try again.
Hope it sticks is another way of saying that I don’t understand the MOA.
Yep. In all reality, we need to keep people from getting to the severe/critical stage of Covid and dying. I wonder....
Yes sir. Industry Disrupting Molecule. This is why I hold.
Same to you!
Couple that with continued trial action instead of a halt for safety or lack of efficacy... and then there’s also this on top of it:
https://endpts.com/covid-19-roundup-novartis-treatment-comes-up-short-in-phiii-humanigen-expands-trial-but-draws-criticism/
From the tweet of Robert Kruse, Md, PhD
“For those scoring at home, antibodies against IL-1beta, IL-6, and IL-6R all failed in clinical trials for hospitalized COVID-19 cases w/ pneumonia & CRS. Steroids do help, however, targeting many immune and non-immune pathways in a broad manner.”
Leronlimab continues to plow ahead while others are earning nails in their coffins.
This is true. This is big pharma article. They either don’t know, or don’t think it matters, that Cytodyn is leading the mABs when it comes to Covid trials for severe/critical.
The truth is that it doesn’t matter. When the trial is finished and we have data, THAT’S what is going to matter.
Have a great day.
And then there’s this: https://news.yahoo.com/exclusive-led-covid-drug-scheme-125404769.html
Oh I bet. You can’t keep a drug like this away from the world forever. SOMEBODY is going to approve it!
There goes those darned PRs and data again. Just a matter of time before approval in US or U.K. Don’t care which, as Leronlimab continues to press on. Longs are not really worried about today’s numbers. There’s a big picture being put together, and that day will be rewarding.
Well, considering there is actual data supporting the PR, I’ll stick with PRs and data. As usual. The buyer’s strike piece is like a resurrection cookie. Looks good on the outside, but nothing of substance.
https://www.sciencedirect.com/science/article/pii/S0092867419301072
Summary
We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-?32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.
Current DSMB advise to continue the severe/critical Covid study as well as Remdesivir approval, in my opinion, are indirect proofs that results will be fantastic, and a threat to Big Pharma.
Clock is ticking.
This would be awesome. More for the fact that medications that actually can demonstrate a benefit through clear MOA. The plus side is that when Leronlimab demonstrates itself in cd12 final data, there will be no denying its efficacy.
Exactly right. There’s a good reason the US has the processes it does, but that also means a delay in promising meds, along with political clout.
Other countries don’t all share that. Whatever gets Leronlimab to the market and helping people the soonest, the better. We already know it’s safe.